Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Down 25.2% in December

Bone Biologics Corp. (NASDAQ:BBLG) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 40,434 shares, a decline of 25.2% from the December 15th total of 54,072 shares. Currently, 2.4% of the shares of the company are short sold. Based on an average daily volume of 1,479,210 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 1,479,210 shares, the short-interest ratio is currently 0.0 days. Currently, 2.4% of the shares of the company are short sold.

Bone Biologics Stock Performance

NASDAQ BBLG traded up $0.11 during trading on Friday, reaching $1.78. 142,283 shares of the company traded hands, compared to its average volume of 873,884. Bone Biologics has a 1-year low of $1.30 and a 1-year high of $7.74. The stock’s 50 day moving average price is $1.68 and its two-hundred day moving average price is $2.20. The company has a market cap of $3.20 million, a price-to-earnings ratio of -0.49 and a beta of 0.74.

Bone Biologics (NASDAQ:BBLG) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.86. Equities research analysts expect that Bone Biologics will post -5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BBLG has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Bone Biologics in a report on Monday, December 22nd. Wall Street Zen upgraded shares of Bone Biologics from a “sell” rating to a “hold” rating in a research report on Sunday, September 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.